Trevena

Revolutionary Preclinical Data Unveiled by Trevena: Potential New Direction in Neuropathic Pain and Acute Seizure Management

CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), announced key data today from two separate preclinical studies. The data provides fascinating insights into the potential effects of TRV045, a novel S1P1 …

Revolutionary Preclinical Data Unveiled by Trevena: Potential New Direction in Neuropathic Pain and Acute Seizure Management Read More



NRx Pharmaceuticals

NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain

RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)  announced the recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of …

NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain Read More